Zac McDonald1, Qixin Liu1, Mingjie Xie1, Paul Taylor1, and Bin Ma1,2
1Rapid Novor, Inc, Kitchener, Ontario, Canada
2University of Waterloo, Waterloo, Ontario, Canada

Abstract

Monoclonal antibodies (mAbs) are widely used in research, diagnosis, and pharmaceutical purposes. Lately, the relatively lower quality of research-purpose mAbs is a point of concern within the research community. The problems include the lack of validation and low reproducibility. As most of the validation is done via immunoassay, the extent of protein contamination, including undesired antibody forms, remains unknown. Mass spectrometry-based protein sequencing technology enables the discovery and characterization of undesired antibody forms in mAb reagents. In this study, we examine the existence of a second light chain in addition to the expected primary light chain. To our surprise, a significant portion of the mAbs we studied included a second light chain that can be completely or partially de novo sequenced via mass spectrometry.

Key Takeaways

  • De novo protein sequencing is capable of identifying additional antibody chains
  • De novo protein sequencing can decode antibody sequences regardless of the isotype or the host species
  • Secondary light chains may affect antibody binding and contribute to poor reproducible results
  • Reproducibility is a cornerstone of the immunoreagent industry
  • De novo protein sequencing can be used to secure reproducibility of immunoreagents

Download the Full Case Study

Whitepaper: Prevalence of Secondary Light Chains

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 3000 antibodies and we are eager to help you.